Indication
Acute Lymphocytic Leukemia
40 clinical trials
72 products
16 drugs
Clinical trial
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors in Pediatric ParticipantsStatus: Recruiting, Estimated PCD: 2024-12-07
Product
PonatinibClinical trial
A Phase I Open, Single-arm Study of JWCAR029 (CD19-targeted Chimeric Antigen Receptor T Cells) for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic LeukemiaStatus: Recruiting, Estimated PCD: 2023-10-31
Product
SAR3419Clinical trial
Phase II Two Stage Finding Run-in Study of SAR3419, An Anti-CD19 Antibody-Maytansine Conjugate, Administered as a Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaStatus: Terminated, Estimated PCD: 2014-05-01
Product
CyclophosphamideProduct
FludarabineProduct
BusulfanProduct
MesnaClinical trial
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 InhibitorsStatus: Recruiting, Estimated PCD: 2026-06-30
Product
SirolimusProduct
Mycophenolate MofetilProduct
FilgrastimClinical trial
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL GeneStatus: Completed, Estimated PCD: 2016-05-01
Product
EPZ-5676Clinical trial
Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell MalignanciesStatus: Active (not recruiting), Estimated PCD: 2019-04-03
Product
CD22-CARClinical trial
Phase I Study Of CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, Acute Lymphocytic Leukemia, and Chronic Lymphocytic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2014-07-01
Product
CD19CAR-28-zeta T cellsProduct
IpilimumabClinical trial
A Clinical Study of Chimeric Antigen Receptor T Cells Combined With Eps8 Peptide Specific Dendritic Cell for Patients With Relapsed/Refractory Leukemia and Myelodysplastic SyndromesStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic LeukemiaStatus: Recruiting, Estimated PCD: 2024-05-01
Product
Inotuzumab OzogamicinClinical trial
Phase II Study of INCB018424 in Patients With Advanced Hematologic MalignanciesStatus: Completed, Estimated PCD: 2017-03-23
Product
INCB018424Clinical trial
A Single-Arm, Open-Label, Pilot Study and Expansion Study of JAK Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell TransplantationStatus: Active (not recruiting), Estimated PCD: 2024-06-17
Product
ItacitinibClinical trial
Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesStatus: Recruiting, Estimated PCD: 2027-07-01
Drug
cyclophosphamideDrug
fludarabineClinical trial
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesStatus: Recruiting, Estimated PCD: 2025-12-01
Product
CD19/CD22 CAR T-CellsClinical trial
A Phase 1/1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of LP-118 in Subjects With Relapsed or Refractory Hematological MalignanciesStatus: Recruiting, Estimated PCD: 2025-10-01
Product
LP-118Clinical trial
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic MalignanciesStatus: Withdrawn, Estimated PCD: 2027-04-01
Clinical trial
Phase I Study of Activated T-Cells Expressing Second or Third Generation CD19-Specific Chimeric Antigen Receptors for Advanced B-Cell Non-Hodgkin's Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia (SAGAN)Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Allogeneic Peripheral Blood Stem Cell Transplantation With Minimally Myelosuppressive Regimen of Pentostatin and Low-dose Total-body IrradiationStatus: Completed, Estimated PCD: 2008-12-30
Product
PentostatinProduct
Cyclosporine ADrug
FilgrastimClinical trial
A Phase I Trial Using In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell MalignanciesStatus: Active (not recruiting), Estimated PCD: 2026-09-01
Clinical trial
A Reduced Intensity Conditioning With Clofarabine Antithymocyte Globulin and Total Lymphoid Irradiation Followed by Allogeneic Hematopoietic Stem Cell TransplantationStatus: Completed, Estimated PCD: 2020-12-01
Product
Antithymocyte GlobulinProduct
ClofarabineClinical trial
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological DiseasesStatus: Recruiting, Estimated PCD: 2024-10-01
Product
Mycophenylate mofetilProduct
Umbilical cord bloodClinical trial
Multi-institutional Prospective Pilot Study of Radiology Evaluation of Acute Leukemia Infiltration analyZed by Experimental ImagingStatus: Recruiting, Estimated PCD: 2025-03-01
Product
FLTClinical trial
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-253 in Adult Patients With High Grade Myeloid Malignancies and Acute Lymphocytic Leukemia, Lymphoma and Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-11-01
Drug
KT-253Clinical trial
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological DiseasesStatus: Recruiting, Estimated PCD: 2027-10-22
Product
AllopurinolProduct
Bone Marrow Cell TransplantClinical trial
Single-Arm, Open Label, Interventional Phase II Clinical Trial Evaluating MGTA-456 in Patients With High-Risk MalignancyStatus: Active (not recruiting), Estimated PCD: 2020-06-23
Drug
MelphalanProduct
MGTA 456Clinical trial
A Phase I, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-AIO, a Triple-targeted Cell Preparation Targeting CD19/CD20/CD22, in Patients With Relapsed/Refractory B-cell Acute Lymphocytic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Product
LCAR-AIOClinical trial
Dose Escalation Study Phase I/II of Umbilical Cord Blood-Derived CAR-Engineered NK Cells in Conjunction With Lymphodepleting Chemotherapy in Patients With Relapsed/Refractory B-Lymphoid MalignanciesStatus: Completed, Estimated PCD: 2023-03-06
Product
AP1903Clinical trial
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases [MT2015-32]Status: Completed, Estimated PCD: 2023-04-17
Drug
AllopurinolProduct
ATGDrug
VarlilumabProduct
Peripheral Blood Stem CellsProduct
Bone Marrow CellsClinical trial
A Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage LeukemiaStatus: Recruiting, Estimated PCD: 2027-03-01
Drug
TafasitamabClinical trial
Pilot Study for Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic LeukemiaStatus: Completed, Estimated PCD: 2003-06-01
Drug
doxorubicinProduct
CytarabineDrug
lenalidomideProduct
IdarubicinProduct
IfosfamideDrug
DocetaxelProduct
MercaptopurineProduct
VM26Drug
R-CHOPClinical trial
Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93)Status: Completed, Estimated PCD: 1999-01-01
Product
AsparaginaseProduct
DaunorubicinProduct
MitoxantroneProduct
6-MercaptopurineProduct
6-ThioguanineProduct
Dexamethasone / PrednisoloneClinical trial
German Multicenter Phase II Trial to Study Effectivity and Feasibility of Alemtuzumab (MabCampath®) in T-ALL and T-Lymphoblastic Lymphomas With Minimal Residual Disease (MRD), in Refractory Relapse or in Primary FailureStatus: Completed, Estimated PCD: 2008-04-01
Product
AlemtuzumabProduct
CladribineClinical trial
Multicenter Trial for Treatment of Acute Lymphocytic Leukemia in Adults (Pilot Study 06/99)Status: Completed, Estimated PCD: 2003-11-01
Product
Vincristine + VindesineDrug
etoposideClinical trial
Phase II Study of Timed Sequential Busulfan in Combination With Fludarabine in Allogeneic Stem Cell TransplantationStatus: Completed, Estimated PCD: 2022-08-11
Product
ThioguanineClinical trial
Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2)Status: Completed, Estimated PCD: 2011-06-01
Product
Dexamethasone + PrednisoloneProduct
HDARACProduct
DepocyteClinical trial
A Single-Arm Phase I/II Study Evaluating the Safety and Clinical Efficacy Of the 2-nd Generation CD19 Autologous CAR T Cells on the CliniMACS Prodigy Automated Manufacturing Platform in Treatment of Paediatric And Young Adult Patients With Relapsed/Refractory B-lineage Acute Lymphoblastic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2020-10-15
Drug
TocilizumabProduct
EtoposideClinical trial
An Open-label, First-in-human, Dose-escalation/Expansion Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Adult and Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Status: Recruiting, Estimated PCD: 2025-12-11
Product
SAR443579Clinical trial
Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic MalignanciesStatus: Completed, Estimated PCD: 2019-11-05
Clinical trial
AUGMENT-102: A Phase 1, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability and Preliminary Anti-Leukemic Activity of SNDX-5613 in Combination With Chemotherapy in Patients With Relapsed/Refractory Leukemias Harboring Alterations in KMT2A/MLL, Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) GenesStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Product
RevumenibProduct
Chemotherapy Regimen 1Product
Chemotherapy Regimen 2Clinical trial
Phase I Dose Escalation and Dose Expansion Study of Duvelisib Following Chimeric Antigen Receptor T-Cell TherapyStatus: Recruiting, Estimated PCD: 2025-12-31
Product
DuvelisibProduct
Total Body IrradiationProduct
TacrolimusClinical trial
A Phase 1/2 Single-center Study Evaluating the Safety and Efficacy of TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in Adults With Refractory/Relapsed B-cell Acute Lymphoblastic LeukaemiaStatus: Recruiting, Estimated PCD: 2026-07-01